Radiopharm Theranostics Limited
ASX: RAD
Radiopharm advances clinical pipeline, but weak technical trend and funding reliance weigh on outlook.
(Source: TradingView) 3-Month Performance Profile of RAD on a DTF compared to S&P/ASX 200 (XJO).
Radiopharm Theranostics Limited released encouraging interim results from its Phase 2b RAD101 study, where 92% of evaluable patients showed c
🔒
Subscribers only
Sign in with your subscriber account or subscribe to access this research report.
Required subscription
Daily Digest
A$200.00
Already a subscriber?
Sign in to read this report.
Required subscription
Daily Digest
Stay informed with expert daily ASX research covering four carefully selected stocks, complete with market insights, risk ratings, and clear Buy, Hold, or Sell general guidance—delivered before the market opens each trading day.
- ✓ Four Expert-Selected ASX Stocks Daily
- ✓ Weekday Pre-Market Delivery
- ✓ In-Depth Research & Analysis
- ✓ Access to All Previous Reports
A$200.00/ 12 months
Risk:Medium
Subscribe Now →
